Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox vs Olanzapine on weight in schizophrenia
NCT00380224Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2006
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bifeprunox in schizophrenia, sponsored by Pfizer. Primary endpoint: Change from baseline on body weight at 8 weeks. Started Jul 2006; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00380224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380224.